Novavax Inc (NVAX) USD0.01

Sell:$7.47Buy:$7.48$0.11 (1.45%)

NASDAQ:1.15%
Market closed |
Prices delayed by at least 15 minutes
Sell:$7.47
Buy:$7.48
Change:$0.11 (1.45%)
Market closed |
Prices delayed by at least 15 minutes
Sell:$7.47
Buy:$7.48
Change:$0.11 (1.45%)
Market closed |
Prices delayed by at least 15 minutes

Company Information

About this company

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Key people

John C. Jacobs
President, Chief Executive Officer, Director
James Patrick Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Ruxandra Draghia-Akli
Executive Vice President, Head of Research & Development
Elaine O'hara
Executive Vice President, Chief Strategy Officer
Robert Walker
Senior Vice President, Chief Medical Officer
Margaret G. Mcglynn
Independent Chairman of the Board
Gregg Huber Alton
Independent Director
Richard H. Douglas
Independent Director
Rachel K. King
Independent Director
David M. Mott
Independent Director
Click to see more

Key facts

  • EPIC
    NVAX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6700024010
  • Market cap
    $1.22bn
  • Employees
    952
  • Shares in issue
    164.74m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.